Bringing the fundamentals into focus…
Back to Akebia Therapeutics, Inc.
How Akebia Therapeutics, Inc. stacks up
AKBA · against 454 other Healthcare companies listed in US-listed
Growth
48/ 100
Below the middle of the pack.
Ranked #298 of 455 · scores higher than 33% of peers
Bars: peers in each 10-point band of the growth score25 peers with a growth score of 40–49, including AKBA · Click a bar to see the companies
Why growth scores 48?
Weighted metrics compared with all Healthcare companies.Its metrics sit close to the Healthcare norm.
- slower revenue growth over three years: weaker than 62% of peers. 3-year revenue growth: 2.9% vs peer median 5.8%
- Still loss-making, but the loss per share narrowed. Earnings per share growth: — vs peer median 9.8%
- Revenue growth is close to the peer norm. Revenue growth: 7.5% vs peer median 6.1%
Metric by metric
Position: dot = AKBA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | AKBA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Revenue growthHigher is better · 475 reported | 7.5% | 11.0% | 42% | 33% | |
| Earnings per share growthHigher is better · 171 reported | Not reported | 21.2% | — | — | 33% |
| 3-year revenue growthHigher is better · 433 reported | 2.9% | 11.0% | 27% | 33% |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by growth score
Top 5 and the companies ranked around AKBA| Rank | Company | Market cap | Growth | Overall |
|---|---|---|---|---|
| 1 | 464M USD | 100 | 53 | |
| 2 | 1.4B USD | 99 | 73 | |
| 2 | 433M USD | 99 | 81 | |
| 2 | 8.8B USD | 99 | 31 | |
| 2 | 90M USD | 99 | 27 | |
| 295 | 116.9B USD | 49 | 47 | |
| 295 | 6.6B USD | 49 | 61 | |
| 295 | 100.2B USD | 49 | 68 | |
| 298 | 49.5B USD | 48 | 53 | |
| 298 | 201M USD | 48 | 24 | |
| 298 | 969M USD | 48 | 54 | |
| 298 | 641.4B USD | 48 | 59 | |
| 298 | 519M USD | 48 | 22 | |
| 298 | 18.5B USD | 48 | 54 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score